Anavex is Amarantus' first customer, but the company is "currently in active discussions with both emerging and large pharma companies" to expand its customer base for its Alzheimer's biomarker services, Amarantus CEO Gerald Commissiong said in a statement.

"We are positioning Amarantus Diagnostics to be the market leader in Alzheimer's blood-based biomarkers for the Investigational Use Only (IUO) market, and we believe this agreement is the first important revenue generating step in this direction for Amarantus," Commissiong said.